A股異動 | 浙江富潤(600070.SH)漲停 公司控制權或發生變動
格隆匯6月11日丨浙江富潤(600070.SH)今天覆牌一字板漲停,報8.15元創四個月新高,最新總市值42.54億,現有封單26萬餘手。公司10日發佈公吿稱,控股股東富潤集團擬將持有的公司4698萬股(佔公司總股本的9%)轉讓給國信華夏,每股轉讓價8.46元。此外,富潤集團根據項目情況將其持有的不低於公司5.24%股權的投票權委託給股份受讓主體,屆時富潤集團持有公司有表決權的股份數量將低於股份受讓主體,公司控制權將發生變動。國信華夏是中國發展與改革委員會下屬國家信息中心全資持有的全民所有制企業——中國國信信息總公司全資持有的信息科技和大數據業務資產運營和投資控股平台公司。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.